Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show
|
By LabMedica International staff writers Posted on 02 Aug 2018 |

Image: The VITROS XT 7600 Integrated System (Photo courtesy of Ortho Clinical Diagnostics).
Ortho Clinical Diagnostics (Raritan, NJ, USA), a global in vitro diagnostics company, officially unveiled the VITROS XT 7600 Integrated System at the 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo. Ortho also displayed additional clinical lab and immunohematology analyzers and other solutions at the conference held July 29 - August 2 in Chicago, Illinois, USA. Additionally, the company presented seven scientific posters highlighting the performance of assays that are part of its offerings for sepsis, Chagas, diabetes and other conditions.
Ortho is a global in vitro diagnostics company serving the clinical laboratory and immunohematology communities. The company provides sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories. Ortho's blood typing products for the immunohematology community help ensure that every patient receives safe, right type and right unit of blood.
On display at this year’s AACC was Ortho's latest analyzer to receive CE Mark, the VITROS XT 7600 Integrated System, which combines proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously. Other products displayed by Ortho at the event included VITROS 3600 Immunodiagnostic Systems, VITROS 4600 Chemistry Systems, VITROS 5600 Integrated Systems, VITROS Automation Solutions and its immunohematology analyzers, ORTHO VISION and ORTHO VISION Max. Visitors at the company’s booth also explored its virtual reality experience LabBuilder, which allows users to re-imagine what is possible by creating a digital lab that fits their needs.
"Ortho is committed to innovation that helps our customers achieve their goals of enhancing medical value while increasing efficiency," said Robert Yates, chief operating officer for Ortho. "We're delighted to officially reveal at AACC Ortho's VITROS XT 7600, which introduces fundamental change to the way labs operate, and to present insightful posters in the areas of cardiology, infectious disease and endocrinology."
Ortho is a global in vitro diagnostics company serving the clinical laboratory and immunohematology communities. The company provides sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories. Ortho's blood typing products for the immunohematology community help ensure that every patient receives safe, right type and right unit of blood.
On display at this year’s AACC was Ortho's latest analyzer to receive CE Mark, the VITROS XT 7600 Integrated System, which combines proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously. Other products displayed by Ortho at the event included VITROS 3600 Immunodiagnostic Systems, VITROS 4600 Chemistry Systems, VITROS 5600 Integrated Systems, VITROS Automation Solutions and its immunohematology analyzers, ORTHO VISION and ORTHO VISION Max. Visitors at the company’s booth also explored its virtual reality experience LabBuilder, which allows users to re-imagine what is possible by creating a digital lab that fits their needs.
"Ortho is committed to innovation that helps our customers achieve their goals of enhancing medical value while increasing efficiency," said Robert Yates, chief operating officer for Ortho. "We're delighted to officially reveal at AACC Ortho's VITROS XT 7600, which introduces fundamental change to the way labs operate, and to present insightful posters in the areas of cardiology, infectious disease and endocrinology."
Latest AACC 2018 News
- Mesa Biotech Showcases PCR Testing Platform at Clinical Expo
- Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018
- Abbott Diagnostics Displays Alinity Family of Systems
- Roche Diagnostics Highlights Latest Clinical Lab Solutions at AACC
- Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology
- Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers
- Thermo Fisher Scientific Showcases Product Portfolio at Lab Trade Show
- EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018
- Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo
- Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio
- Beckman Coulter Features New Hematology Analyzers and Lab Automation
- Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers
- Orion Diagnostica Showcases Rapid Test and Molecular Platform at Lab Show
- Saladax Biomedical Launches Game-Changing Assays at AACC 2018
- SeraCare Life Sciences Promotes New AccuSpan Panel at Lab Expo
- Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers
Channels
Clinical Chemistry
view channel
Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
Cerebrovascular disease damages blood vessels in the brain and can contribute to tissue injury, microbleeds, white matter damage, stroke, cognitive decline, and dementia. Identifying people at higher risk... Read more
Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL), requires accurate identification to guide further evaluation, monitoring, and treatment. In 2026, an estimated 79,320 people in the U.... Read moreMolecular Diagnostics
view channel
Blood RNA Test May Detect Precursors to Ovarian Cancer
High-grade serous ovarian cancer is often diagnosed at an advanced stage, limiting opportunities for early intervention. The disease frequently originates in the fallopian tube as serous tubal intraepithelial... Read more
Microsatellite Instability Test Gains FDA Approval for Immunotherapy Selection
Microsatellite instability-high (MSI-H) status is a key tumor biomarker used to guide treatment decisions in precision oncology. Testing can identify adult and pediatric patients with unresectable or metastatic... Read more
Blood-Detected Chromosomal Changes May Refine Colorectal Cancer Risk Assessment
Colorectal cancer is among the most common cancers worldwide and a leading cause of cancer-related mortality. Identifying individuals at increased risk could help guide more targeted screening and prevention... Read more
AI Tool Automates Variant Curation and Interpretation for Cancer Whole-Genome Sequencing
Cancer whole-genome sequencing (WGS) provides a comprehensive view of cancer genomes, but interpreting the vast amount of data remains challenging. As WGS gains wider clinical adoption, variant curation... Read moreHematology
view channel
New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more
Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more








